Salud financiera de hoja de balance de Matinas BioPharma Holdings

Salud financiera controles de criterios 6/6

Matinas BioPharma Holdings tiene un patrimonio de los accionistas total de $19.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $25.1M y $5.9M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$8.11m
Patrimonio	US$14.56m
Total pasivo	US$5.05m
Activos totales	US$19.61m

Actualizaciones recientes sobre salud financiera

Recent updates

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($15.5M) de 6LJ superan a sus pasivos a corto plazo ($2.6M).

Pasivo a largo plazo: Los activos a corto plazo de 6LJ ($15.5M) superan a sus pasivos a largo plazo ($3.2M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: 6LJ está libre de deudas.

Reducción de la deuda: 6LJ no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 1.2%.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 6LJ tiene suficiente cash runway para 11 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que 6LJ disponga de suficiente cash runway para 10 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Matinas BioPharma Holdings

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Recent updates

New major risk - Revenue and earnings growth

Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings released: US$0.11 loss per share (vs US$0.097 loss in FY 2022)

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings released: US$0.097 loss per share (vs US$0.11 loss in FY 2021)

Forecast to breakeven in 2025

Third quarter 2022 earnings released: US$0.025 loss per share (vs US$0.032 loss in 3Q 2021)

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Second quarter 2022 earnings released: US$0.027 loss per share (vs US$0.024 loss in 2Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Forecast to breakeven in 2025

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: €1.37

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: €0.84

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Revenue beats expectations

Matinas BioPharma Announces Unanimous DSMB Approval to Progress into Second Cohort of Patients in the EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Cryptococcal Meningitis

New 90-day low - €0.61

Earnings released

New 90-day high - €0.85

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera